Pulmonary hypertension in chronic lung disease and hypoxia
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The OPTN/UNOS registry data demonstrate that Group 3 pulmonary hypertension is common in patients with advanced CF, ILD, and COPD and is associated with increased oxygen requirements and increased mortality.(294–299)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [294]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879
Self-citationSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Self-citationSevere Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
Chaouat, A., Bugnet, A.-S., Kadaoui, N., Schott, R., Enache, I., Ducoloné, A., Ehrhart, M., Kessler, R., & Weitzenblum, E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-006oc · Cited by 714
Pulmonary Hypertension in Chronic Lung Diseases
Seeger, W., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.036 · Cited by 673
Self-citationA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Consensus Statement on Chronic and Subacute High Altitude Diseases
León-Velarde, F., Maggiorini, M., Reeves, J. T., Aldashev, A., Asmus, I., Bernardi, L., Ge, R.-L., Hackett, P., Kobayashi, T., Moore, L. G., et al. (2005) · High Altitude Medicine & Biology · doi:10.1089/ham.2005.6.147 · Cited by 630
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Self-citationKESSLER, R., FALLER, M., FOURGAUT, G., MENNECIER, B., & WEITZENBLUM, E. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9803117 · Cited by 549
Obesity-Associated hypoventilation in hospitalized patients: prevalence, effects, and outcome
Nowbar, S., Burkart, K. M., Gonzales, R., Fedorowicz, A., Gozansky, W. S., Gaudio, J. C., Taylor, M. R. G., & Zwillich, C. W. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.022 · Cited by 512
Clinical features of paediatric pulmonary hypertension: a registry study
Berger, R. M., Beghetti, M., Humpl, T., Raskob, G. E., Ivy, D. D., Jing, Z.-C., Bonnet, D., Schulze-Neick, I., & Barst, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61621-8 · Cited by 508
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
An overview of the 6th World Symposium on Pulmonary Hypertension
Galiè, N., McLaughlin, V. V., Rubin, L. J., & Simonneau, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.02148-2018 · Cited by 526
Metadata
- Authors
- Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., Weissmann, N., & Seeger, W.
- Affiliations
- Inova Fairfax Hospital (US)
- MultiMedica (IT)
- Medical University of Graz (AT)
- Medizinische Hochschule Hannover (DE)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Justus-Liebig-Universität Gießen (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801914
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351338
- OpenAlex
- W2904463477
- Cited by
- 757
- References
- 94
- Citations by year
- 2026: 54 · 2025: 104 · 2024: 141 · 2023: 96 · 2022: 122 · 2021: 114 · 2020: 76 · 2019: 44
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc)
- Funders
- American Thoracic Society
- Pfizer
- AstraZeneca
- Bayer
- GlaxoSmithKline
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- United Therapeutics Corporation
- Sunovion
- Veracyte
- York University
- National Institutes of Health
- Genentech
- Actelion Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- pulmonary hypertension, chronic lung disease, hypoxia, hemodynamic assessment, quality of life, mortality risk, oxygen requirement
- MeSH terms
- Animals, Hypoxia, Antihypertensive Agents, Chronic Disease, Humans, Hypertension, Pulmonary, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pulmonary hypertension in chronic lung disease and hypoxia. https://app.cochat.ai/papers/10.1183/13993003.01914-2018
- The paper
- Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., Weissmann, N., & Seeger, W. (2019). Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal. https://doi.org/10.1183/13993003.01914-2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.